EcoDrugPlus

Bcl2 Apoptosis Regulator

Ensembl ID : ENSOKIG00005043796
Gene Symbol: BCL2
3 Cross references
170 Possible Orthologues:

Bcl2 Apoptosis Regulator

Ensembl ID : ENSOKIG00005016369
Gene Symbol: BCL2
3 Cross references
170 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSOKIG00005014496
Gene Symbol: BCL2L1
3 Cross references
215 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSOKIG00005000981
Gene Symbol: BCL2L1
3 Cross references
215 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSOKIG00005019670
Gene Symbol: BCR
3 Cross references
199 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSOKIG00005050870
Gene Symbol: BCR
3 Cross references
198 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSOKIG00005029800
Gene Symbol: BTK
3 Cross references
202 Possible Orthologues:

C-C Chemokine Receptor Type 9-Like

Ensembl ID : ENSOKIG00005045442
Gene Symbol: LOC109872235
3 Cross references
182 Possible Orthologues:

C-C Chemokine Receptor Type 9-Like

Ensembl ID : ENSOKIG00005037940
Gene Symbol: LOC109909118
2 Cross references
185 Possible Orthologues:

C-X-C Chemokine Receptor Type 1-Like

Ensembl ID : ENSOKIG00005017978
Gene Symbol: LOC109871297
2 Cross references
268 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSOKIG00005006161
Gene Symbol: CXCR4
3 Cross references
195 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSOKIG00005017980
Gene Symbol: CXCR4
3 Cross references
195 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).